Get started

TECH

Xiaomi bottomed - We are heading towards new All-time highs!Hey Investor, please see my current idea on the Xiaomi stock, where my count suggests a possible bottom for a trend reversal in order to make new highs. This is calculated based on my Elliot Waves Count by the fact, that wave C has the same length as wave a. I have checked the inner structure of wave C in order to check the inner structure of this wave. Based on this knowledge I am very confident that we might have our bottom here. Let me know what you think. This is no financial advice, just my technical view. RT
HKEX:1810
by RT_Trading_
1
$NDQ #QQQ $QQQ pulling a Wu-Tang patternlooking at the 1hr chart, there is a classic W pattern formation going on here. December was a tough month for tech, and looks to be finally recovering. This weeks moves show a break above the prior down channel, with tightly wound consolidation. TBH I see this going in either direction, but with the tax loss harvesting done for 2021, my money is on volume buy-ins this month, with a beginning of a reversal in March when tapering is ending and rates are set to go up. NFA
TVC:NDQ
by corgicapitalllc
Hello Group lost big support levelThis stock has been slashed over this year. It has lost an important support level and it's following the same trend as other companies such as Robinhood, Bumble, Victoria's Secret, Vimeo or Deliveroo + the Chinese Crisis. We expect someday a trend reversal, so for now we recommend to place price alerts. Key level, the weekly resistance line (at $12 per share - a good one for selling-short). Moreover, it's not a bad entry for swing traders with stop loss on last lows, as a bullish divergence on the daily chart is almost complete.
NASDAQ:MOMO
by alvaromroo
1
Novacyt ALNOV Graham Mullis, CEO of the Novacyt Group, commented: “Novacyt continues to process COVID-19 tests for current and future demand. We continue to ensure that innovation is at the center of our strategy and that our growing portfolio of COVID-19 tests is available to clients in private and public healthcare facilities to expand existing partnerships and support new partnerships. Throughout the pandemic, the demand for NHS testing has remained a key priority for the company and the award of the contract under the National PHE Microbiology Framework is a testament to our continued commitment. “We believe that our long-term strategy also supports the growth of Novacyt after COVID-19. In particular, our progress and growth potential in the private sector will not only help us maximize the opportunity for COVID-19 testing, but also ensure that we are well positioned, along with technologies and partners, for sustainable growth. beyond COVID-19. We therefore believe that Novacyt is well placed to continue to develop its business transformation. " This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. About the Novacyt Group The Novacyt Group is an international diagnostic company generating a growing portfolio of in vitro and molecular diagnostic tests. Its main strengths lie in the development, marketing, design and manufacture of diagnostic products. The main business units of the Company include the Primerdesign and Lab21 products, providing a wide range of high quality assays and reagents worldwide. The Group directly serves the microbiology, hematology and serology markets as well as its global partners, including large companies.
EURONEXT:ALNOVLong
by wallstreetstocks